Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Proteonomix Announces Restructuring

PARAMUS, N.J., Jan. 8, 2013 /PRNewswire/ -- Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has caused the formation of a BVI corporation that will receive sublicenses and assignments of technology previously licensed to the Company so as to facilitate future financing and operations.

Michael Cohen, President and CEO of the Company, stated, "We formed a BVI corporation, Proteonomix, Ltd., that will issue to all shareholders of record at the close of business on January 11, 2013, the same number of shares that they own at the close on that date, without further payment of any sort whatsoever." "We have decided to do this to assure shareholders that the new sublicenses and assignments of licenses to the BVI corporation will not impact such shareholders' participation in the successes, or failures, of the Company's present clinical trial or our planned future activities."  "We plan to leave the StromaCel technology in the Company and change the name of the Company to StromaCel, Inc.  The diabetes technology present in the licensed technology left behind is what started me on the quest that became our Company. We intend to continue this work, which will hopefully culminate with a solution to Type I diabetes that has my wife among its victims. This Company began many years ago with the intent to cure her and my commitment to continue that work is still resolute."

Mr. Roger Fidler, General Counsel and Treasurer of the Company, stated: "We undertake this restructuring and will establish a trading market outside of the United States on the GXG, to seek financing outside of the United States. At this point we have cash on hand sufficient to seek additional offshore financing in order to advance the current and future IP that the company has licensed."

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at www.proteonomix.com and www.proteoderm.com.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

SOURCE Proteonomix, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
We often get asked “Should I use GridFS for file storage with MongoDB”. As with most things, the answer is a staunch “it depends”. GridFS looks like a great idea on paper - a virtual filesystem held within MongoDB which allows for larger than 16MB files to be held, synced and replicat...
The supply chain is evolving, and buyers need to analyze and predict, but also to manage risk. When Capgemini's business information management (BIM) practices unit needed to provide big data capabilities to its insurance company customers, it needed to deliver the right information t...
Some people believe good or bad things always happen in threes. I believe you will always be able to find three (and probably more) things that are good or bad and somewhat related, but sometimes I get surprised by the apparent coincidental appearance of several closely related “things...
This article defines long polling and presents a few techniques on how long polling could be used in Spring MVC web applications. Discussion covers both the AJAX and the server part of the solution as well as outlines a few possible options for implementation. The article compares perf...
Red Hat, Inc., on Wednesday announced that it has signed a definitive agreement to acquire eNovance, a provider of open source cloud computing services. Combined with Red Hat’s existing leadership in OpenStack, the addition of eNovance’s systems integration capabilities and engineering...
Hear from Red Hat leaders and industry experts on Tuesday, June 10, 2014, at 11am and see how Red Hat Enterprise Linux continues to deliver unmatched customer value, increased efficiency, and true strategic advantage for global customers across every industry. Attendees will learn mor...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE